Endologix, Inc. (ELGX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Endologix, Inc. (NASDAQ:ELGX) have earned an average recommendation of “Hold” from the twelve brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.36.

A number of research firms have recently commented on ELGX. Royal Bank of Canada cut their target price on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 8th. JPMorgan Chase & Co. cut shares of Endologix from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. ValuEngine cut shares of Endologix from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Stifel Nicolaus cut their target price on shares of Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Endologix by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock valued at $32,262,000 after acquiring an additional 353,233 shares in the last quarter. Redmile Group LLC grew its stake in Endologix by 134.4% during the 2nd quarter. Redmile Group LLC now owns 6,368,299 shares of the medical instruments supplier’s stock valued at $30,950,000 after acquiring an additional 3,650,905 shares in the last quarter. State Street Corp grew its stake in Endologix by 11.5% during the 2nd quarter. State Street Corp now owns 1,951,432 shares of the medical instruments supplier’s stock valued at $9,483,000 after acquiring an additional 201,700 shares in the last quarter. Northern Trust Corp grew its stake in Endologix by 5.0% during the 2nd quarter. Northern Trust Corp now owns 1,104,943 shares of the medical instruments supplier’s stock valued at $5,369,000 after acquiring an additional 52,755 shares in the last quarter. Finally, Cortina Asset Management LLC grew its stake in Endologix by 15.2% during the 3rd quarter. Cortina Asset Management LLC now owns 835,723 shares of the medical instruments supplier’s stock valued at $3,727,000 after acquiring an additional 110,062 shares in the last quarter.

Shares of Endologix (NASDAQ ELGX) opened at $4.27 on Friday. The company has a market cap of $354.68, a PE ratio of -4.59 and a beta of 0.72. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. Endologix has a one year low of $4.08 and a one year high of $7.66.

Endologix (NASDAQ:ELGX) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. research analysts forecast that Endologix will post -0.68 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Endologix, Inc. (ELGX) Receives Consensus Recommendation of “Hold” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/19/endologix-inc-elgx-receives-consensus-recommendation-of-hold-from-analysts-2.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply